11.87
-16.59 (-58.29%)
| Penutupan Terdahulu | 28.46 |
| Jumlah Dagangan | 4,024,864 |
| Harga / Buku (P/B) | 4.06 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -3.76 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.07% |
| Nisbah Semasa (MRQ) | 14.34 |
| Aliran Tunai Operasi (OCF TTM) | -119.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -54.54 M |
| Pulangan Atas Aset (ROA TTM) | -23.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -49.00% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | ArriVent BioPharma, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 9.74% |
| % Dimiliki oleh Institusi | 85.20% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| General Catalyst Group Management, Llc | 30 Jun 2026 | 1,494,786 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |